Ilyang Pharmaceutical KRX:007570KOSPI

일양약품 · Korean news coverage and regulatory filings, organized.

Articles, 24h0
Articles, 7 days9
DART filings, 7 days4
Articles tracked9since Sep 11

In Q2 2026, Ilyang Pharmaceutical reported revenue of ₩65.1bn, up 3.9% year on year, and an operating loss of ₩6.8bn. Ilyang Pharmaceutical (일양약품) appeared in 9 Korean news articles and 4 DART filings over the past seven days. Coverage peaked on Sep 11 with 9 articles. The most common catalyst was contracts & orders (1).

Ilyang Pharmaceutical quarterly results consolidated, KRW

QuarterRevenueYoYOperating profitNet income
Q2 2026₩65.1bn+3.9%−₩6.8bn−₩2.3bn
Q1 2026₩65.1bn+5.0%−₩7.4bn₩17.0bn
Q4 2025 derived₩78.9bn+825.7%₩566m−₩5.6bn
Q3 2025₩68.8bn-30.6%−₩158m₩8.4bn
Q2 2025₩62.7bn+7.2%₩1.2bn₩613m
Q1 2025₩62.0bn+5.5%₩3.4bn₩3.8bn
Q4 2024 derived₩8.5bn+2284.0%−₩43m₩2.2bn
Q3 2024₩99.1bn-1.5%₩5.5bn₩3.8bn

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases.

Ilyang Pharmaceutical top stories 2 weeks, by number of outlets

  1. 1
    일양약품 전(前) 홍보실장 유방희 이사 별세
    8 outlets · 8 articlesFirst report Sep 11 14:23 메디팜스투데이
  2. 2
    '슈펙트' 러시아 수출 계약 무산…일양약품, '불성실공시법인' 지정예고
    1 outlets · 1 articlesFirst report Sep 11 08:38 EBNOrder / supply contract

Latest Ilyang Pharmaceutical news Korean headlines